

camurus®

Company presentation

September 2025



Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Camurus snapshot



Rapidly growing commercial stage company

Leader in opioid dependence treatment with Buvidal® and Brixadi® weekly and monthly depots



Advancing late-stage pipeline with blockbuster potential

Prospect for multiple new approvals in endocrinology and rare disease indications



Unique FluidCrystal® technology platform

Commercially validated with a broad range of applications



Strong operational and financial performance

Sustainable profitability since 2022

Listed on
Nasdaq Stockholm
Ticker **CAMX**;
Employees: **275+**

Strategy for continued value creation

- 1 Grow Buvidal/Brixadi sales and expand to new markets
- 2 Advance R&D pipeline to new approvals and launches
- 3 Diversify and grow through business development
- 4 Drive operational excellence and sustainable profitability

Camurus' vision 2027

Sustainable value creation for all stakeholders:

5x

Five-fold revenue growth (to SEK 4.5 billion)



Establishment of US commercial infrastructure

4

Approvals for four R&D pipeline programs

~50%

Operating margin around 50 percent

Significant recent progress

Commercial execution



- Global leadership in long-acting treatment of opioid dependence
- Double-digit Buvidal sales growth in Europe, Australia and MENA
- Best-in-class US launch of Brixadi
- Establishment of own commercial infrastructure in the US

Advancing R&D pipeline



- Ocyyesa® approved in the EU and UK for the treatment of acromegaly
- Positive results from POSITANO Phase 2b study main part
- SORENTA Phase 3 study advancing in GEP-NET
- Clinical study of once-monthly semaglutide, CAM2056


Corporate development



- Solid financial performance with high profitability
- Meaningful investment in R&D and US infrastructure
- Strong cash position
~ SEK 3.3 billion – no debt
- License agreement with Lilly for FluidCrystal® long-acting incretins


Strong financial development

Revenues



- One-time revenue related to Brixadi US approval
- Revenues excl. one-times for Brixadi US approval

Profit before tax



- One-time revenue related to Brixadi US approval
- Profit before tax excl. Brixadi US approval revenue

Full year 2025 guidance

Revenue

SEK 2.7 – 3.0 billion

+ 45 – 61% vs. 2024


Profit before tax

SEK 0.9 – 1.2 billion


+ 63 – 117% vs. 2024

FluidCrystal[®] extended-release technology

- ✓ Easy and convenient administration
- ✓ Rapid onset & long-acting release
- ✓ Controlled by composition, liquid crystal phase structure and biodegradation
- ✓ Applicable across substance classes
- ✓ Compatible with prefilled syringes, auto-injector pens, and other advanced devices
- ✓ Manufacturing by standard processes



Broad and diversified product portfolio and pipeline



Opioid dependence – an escalating global health crisis

Largest society burden of all drugs¹


- 60 million opioid users worldwide¹
- Escalating US opioid overdose deaths²

High need for better access to care and new treatment alternatives

Significant limitation with current daily medications

- Burdens and stigma of daily medications, limited treatment compliance, medication diversion, misuse and unintended pediatric exposure

High US overdose death rate



¹United Nations: World drug report 2024; ²www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm



Opioid
dependence

camurus®



Buvidal – game changing opioid dependence treatment

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over¹

“Buvidal became my way out”

Justin, Buvidal patient in Australia

Buvidal has demonstrated significant benefits to patients and society

- ✓ Superior treatment outcome and patient satisfaction¹⁻⁴
- ✓ Blocks subjective opioid effects from first dose²
- ✓ Reduces treatment burden and improve quality of life^{4,5}
- ✓ Decrease risk of diversion, misuse and pediatric exposure^{6,7}
- ✓ Provides cost savings⁸

¹Lofwall et al. *JAMA Int. Med.* 2018;178(6): 764-773; ²Walsh et al, *JAMA Psychiatry* 2017;74(9):894-902; ³Frost, M., et al. *Addiction.* 2019;114(8):1416-1426. doi: [10.1111/add.14636](https://doi.org/10.1111/add.14636); ⁴Lintzeris, N., et al. *JAMA Network Open.* 2021;4(5):e219041. doi: [10.1001/jamanetworkopen.2021.9041](https://doi.org/10.1001/jamanetworkopen.2021.9041); ⁵Barnett et al *Drug and Alcohol Dependence* 2021; <https://doi.org/10.1016/j.drugalcdep.2021.108959>; ⁶EPAR for Buvidal; ⁷Dunlop, A. J., et al. *Addiction.* 2021. <https://doi.org/10.1111/add.15627>; ⁸Dunlop, A. Oral presentation at CPDD June 2020.



Global leadership in long-acting opioid dependence treatment

Wide and growing access to Buvidal and Brixadi

- Available across four continents
- Estimated 65,000 in treatment with Buvidal in Europe and Australia end of June 2025


Robust Buvidal sales growth

- 87% CAGR since first launch in 2019
- Target more than 100,000 patients on Buvidal in 2027

Market expansion continues

- Three new markets being introduced in 2025 (Switzerland, Luxembourg, Portugal)
- Four market authorization applications under review

Strong growth of Buvidal sales



Brixadi performance in the US

US opioid crisis continues


- Overall, 6-7 million people with OUD in the US¹⁻³
- Total number of ~2.3 million patients in treatment in 2023 of which ~1.8 million on buprenorphine⁴

Growing Brixadi market share

- Renewed high growth in Q2 after a soft Q1 2025
 - Royalty +32% at CER QoQ
 - Easing temporary headwinds seen in early 2025
- Expanding and protecting access to treatment
 - States allocating funding to expand OUD treatment
 - Federal Medical Assistance Percentage for Medicaid remains at current levels in budget bill
 - Exempts Medicaid substance use disorder patients from the work requirement
- Brixadi LAIB est. share in the US around 25%

Brixadi peak market potential est. > USD 1 bn⁶

Brixadi royalty by quarter



Buvidal/Brixadi – well differentiated

Convenient and flexible administration

- Weekly and monthly dosing
- Multiple dose strengths (four weekly, three monthly)
- Thin needle and small dose volumes
- Room temperature stability (no cold chain required)

Strong scientific evidence base

- Superior efficacy and patient reported treatment satisfaction vs daily standard of care

Competitive label¹

- Switch from daily sublingual buprenorphine using conversion table for dose equivalency

LAI features²

	Once-Monthly Sublocade™	Vivitrol®	Weekly/Monthly Buvidal® Brixadi
Weekly dosing	–	–	✓
Monthly dosing	✓	✓	✓
Multiple doses	–	–	✓
Smallest needle	(19G)	(20G)	✓ (23G)
Lowest dose volume	0.5–1.5mL	3.4mL	✓ 0.16–0.64mL
Room temp. storage	–	–	✓
Clin. data vs active control	–	–	✓
Launched	US, CAN, DE, AUS, SE, FI, IL	US	US, EU, UK, AUS

LAI – long acting injectable

¹Brixadi US label; ²See product information

Growing scientific evidence base

Strong scientific support for Buvidal/Brixadi

– More than 240 scientific publications

Selected recent and planned scientific conference participation in 2025

	Q1/Q2 2025			Q3/Q4 2025		
International	ASAM 24-27 Apr Denver, US	ISAM 26-28 May Hamburg, DE	ALBATROS 10-12 Jun Paris, FR	CPDD 14-18 Jun New Orleans, US	IMiA 29-31 Aug Sydney, AUS	ATHS 21-24 Oct Biarritz, FR
National (selected)	RCGP & AP 16 – 17 January Manchester, UK	APSEP 27-28 March Paris, FR	Addiction Z April – May Gold Coast, AUS	Fed. Addiction 22-23 May Angers, FR	Suchtmedizin 3 – 5 July Munich, DE	Suchtsymp. Oct Grundlsee, AT
	APP Feb Gold Coast, AUS	Sigtunadagarna Apr SE	Subst. Forum. May Mondsee, AT	SEPD 4-7 Jun Madrid, ES	Prison Congr. Oct Montpellier, FR	RCPsych AC&E 9-10 Oct Wales, UK
						Addiktum Nov/Dec Helsinki, Fi

Recent key publications¹⁻³

Substance Abuse and Rehabilitation

Dovepress
Taylor & Francis Group

Open Access Full Text Article

ORIGINAL RESEARCH

Patient Satisfaction and Resource Utilization Following Introduction of Long-Acting Injectable Buprenorphine (LAIB) in Scottish Prisons

Craig Sayers¹, Daniel Mogford²

¹Prison Healthcare, NHS Forth Valley, Stirling, Scotland, UK; ²Camurus Ltd., Duxford, Cambridge, UK

Correspondence: Craig Sayers, Prison Healthcare NHS Forth Valley, National Prison Care Network, c/o HMP Glenochil Health Centre, HMP Glenochil, King O'Muir Road, Tullbody, Clackmannanshire, FK10 3AD, UK. Tel +44 1259 767309, Email craig.sayers@nhs.scot

Journal Pre-proof

Characterizing withdrawal from long-acting injectable buprenorphine: an observational case series.

Running Title: Withdrawal from long-acting injectable buprenorphine

VICTORIA HAYES¹, LLEWELLYN MILLS^{1,2,3}, GAYE BYRON¹, CAROLYN STUBLEY¹, ELEANOR BLACK², BENJAMIN T TREVITT¹, ANDREW A SOMOGYI¹, ARSHMAN SAHID^{1,2}, NICHOLAS LINTZERIS^{1,2,3}.

Drug and Alcohol Dependence Reports 15 (2022) 100328

Contents lists available at ScienceDirect

Drug and Alcohol Dependence Reports

journal homepage: www.elsevier.com/locate/dadr



Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders^{2*}

Rebecca Fish^{1,2}, Céu Mateus¹, Hannah Maiden¹, Euan Lawson¹, Mark Limmer¹

¹ Division of Health Research, Lancaster University, UK
² Lancaster Medical School, Lancaster University, UK



Octreotide SC depot, CAM2029

CAM2029 is a long-acting octreotide in development for three serious rare disease indications

- ✓ Acromegaly
- ✓ Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
- ✓ Polycystic liver disease (PLD)

Designed for enhanced efficacy and patient convenience vs. current somatostatin receptor ligands (SRLs)

CAM2029 designed to address key limitations of current first-generation SRLs


- ✓ Ready-to-use FluidCrystal® technology
- ✓ Rapid onset and long-acting octreotide release¹
- ✓ 5-fold octreotide bioavailability vs Sandostatin LAR with potential for improved efficacy¹⁻³
- ✓ State-of-the-art, pre-filled autoinjector pen enabling convenient patient self-administration
- ✓ Subcutaneous administration with thin needle (22-gauge, 12.5mm)
- ✓ Room temperature storage




CAM2029 provides high SRL exposure

~5x higher octreotide plasma exposure for CAM2029 vs. Sandostatin LAR

- CAM2029 octreotide plasma levels in the range of immediate release octreotide



CAM2029 clinical program overview



Towards a patient-centric acromegaly treatment

Acromegaly is a rare, slowly progressive, chronic and serious condition typically caused by a tumor of the pituitary gland and overproduction of growth hormone. This results in excess growth of bones and tissue and a range of other symptoms and, if untreated, to premature death.




Positive results from ACROINNOVA 1 – CAM2029 provided robust biochemical control

ACROINNOVA 1 study design

- 24-week, randomized, double blind, placebo-controlled Phase 3 study

Patient population


- Biochemically controlled on first-generation SRL*



Superiority achieved

- 77.2% vs. 37.5% patients with $\text{IGF-1} \leq 1 \text{ ULN}$ with CAM2029 versus placebo, $p=0,00018$

IGF-1 levels well controlled



CAM2029 improved

- Treatment convenience
- Acromegaly quality of life
- Patient satisfaction

CAM2029 was well tolerated

- Safety profile comparable to well established profile for first generation SRLs
- Most AEs were mild or moderate and transient injection site reactions and gastrointestinal side-effects
- No serious reactions related to CAM2029


Positive topline results from ACROINNOVA 2

ACROINNOVA 2 study design


- 52-week, open-label safety study with further extension

Patient population

- New patients; uncontrolled or controlled with $\text{IGF-1} < 2 \times \text{ULN}$
- Patients who completed ACROINNOVA 1



Improved acromegaly symptoms with CAM2029



ACROINNOVA 2 results



- Reinforcing long-term safety and effectiveness in ACROINNOVA 1
- Increased response rate from SoC baseline in new recruited patients
- Roll-over placebo patients from ACROINNOVA 1 regained IGF-1 control with CAM2029

Improved patient reported outcomes for CAM2029 vs standard-of-care baseline

- Treatment satisfaction
- Quality of life
- Injection experience

Positive ACROINNOVA 2 extension study data

Improved biochemical response for patients during treatment with CAM2029



TSQM – treatment satisfaction questionnaire for medication

* Transferred to standard-of-care (SoC) – either octreotide LAR or lanreotide Autogel – after completion of ACROINNOVA 2 main part. When ACROINNOVA extension study started, patients were reinvited to join study for another year on CAM2029. Time on SoC between 15 to 95 weeks (median 35 weeks)

Medical information and dissemination of ACROINNOVA results

Pre-launch activities

- Meeting with acromegaly stakeholders
- National and regional advisory board meeting
- Payer engagement and submissions
- Commercial and medical affairs readiness

Scientific conferences in 2025

Q1 2025	Q2 2025	Q3 2025	Q4 2025
ENETS 5-7 Mar Krakow PL	AACE 15-17 May Orlando US	IPS 9-11 Jul San Francisco US	NANETS 23-25 Oct Austin US
DGE 19-21 Mar Baden-Baden DE	ESPE/ESE 10-13 May Copenhagen DK	ENDO 12-15 Jul San Francisco US	ENEA 3-5 Dec Marseille FR
	ACRO	NET	

Rapid fire presentation, educational program and posters of ACROINNOVA results at ENDO¹





Potential to become new standard of care for GEP-NET

Neuroendocrine tumors are cancerous tumors originating from cells in the endocrine and nervous system. The tumors can occur throughout the body, most common they occur in the gastrointestinal tract and lungs. The disease can be chronic with serious symptoms and complications.




SORENTO assessing CAM2029 superiority in PFS vs SoC in patients with GEP-NET

Randomized, active-controlled Phase 3 study

- Randomized, multi-center, open-label, active-controlled Phase 3 study of CAM2029 vs. long-acting octreotide or lanreotide in patients with GEP-NET
- Single trial fulfilling regulatory requirements for safety and efficacy

Patient population

- Patients with confirmed, advanced and well-differentiated GEP-NET (grade 1 to grade 3)



Primary endpoint


- Superiority in progression free survival, PFS, vs. standard of care (first-line medical treatment)
- Assessed after 194 documented PFS events

Secondary endpoints include

- Overall survival
- PROs (e.g., treatment satisfaction, quality of life)
- Safety

Recruitment completed

- Enrollment of 332 patients across 12 countries exceeding randomization target (302)





Positive results from POSITANO in polycystic liver disease

Polycystic liver disease is a rare, genetic, and chronic disorder characterized by progressive growth of cysts in the liver, which can cause severe symptoms and result in impaired quality of life for patients.




Polycystic liver disease

Disease characteristics and prevalence

- Progressive growth of liver cysts of various sizes
- Estimated 37,000 target patients with symptomatic polycystic liver disease (PLD) in US, EU4 and UK¹
- No available pharmacological treatment for PLD

Treatment options

- Somatostatin receptor ligands show promise in clinical studies: decreasing liver volume, symptoms, and improving quality of life in symptomatic patients PLD²⁻⁴
- CAM2029 has orphan drug designation for ADPLD in EU and the US and ongoing applications for PLD associated with AKPKD



POSITANO – Phase 2b study in PLD

Trial design

- 53-week randomized, placebo-controlled, three-arm study
- Open label extension for 120 weeks

Key eligibility criteria

- Symptomatic PLD (isolated or associated with ADPKD)
- htTLV $\geq 1800\text{ml/m}$ at screening

Primary endpoint


- Liver volume change from baseline to week 53 compared to placebo

Key secondary endpoint

- Camurus' developed PRO, PLD-S

Secondary endpoints


- Total liver cyst volume
- Total kidney volume in ADPKD patients
- PLD symptoms and quality of life
- Safety
- PK and immunogenicity




POSITANO met the primary endpoint

Reduction in height adjusted total liver volume change with CAM2029 vs baseline

Main and sensitivity analyses for the primary endpoint Week 53




Treatment difference between CAM2029 groups and placebo




CAM2029 reduces liver cyst volume vs placebo

Total liver cyst volume change from baseline



Difference CAM2029 vs placebo



POSITANO topline results summary for CAM2029

Efficacy conclusions

- **Reduction of liver volume growth vs placebo**
 - Primary endpoint supported by sensitivity analyses
- **Reduction of total liver cyst volume growth vs placebo**
- **Kidney volume reduction indicated in patients with PLD associated with ADPKD**
- **Improved PLD symptoms**
 - Reduction of PLD-S score versus baseline
 - Improved symptoms indicated in several additional PROs (PLD-Q, PGI-S, CGI-S)
- **Robust decrease of IGF-1 vs placebo**

Safety profile

- **Treatment generally well tolerated**
- **Safety profile consistent with that of other injectable SRLs**
- **No new or unexpected safety issues were identified**
- **High study and treatment retention**
- **All eligible patients entered the extension phase**

CAM2029 recent milestones and expected progress ahead

AcroInnova™

Pivotal randomized placebo controlled and long-term safety trials in acromegaly

- ✓ Positive results from ACROINNOVA 1 and 2
- ✓ NDA acceptance in the US – CRL for manufacturer
- ✓ **Positive CHMP opinion in April 2025**
- ✓ **EC market approval in June 2025**
- ✓ **MHRA UK approval in August 2025**
- **NDA resubmission planned for Q3***

SORENTO™

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine Tumors

- ✓ SORENTO Phase 3 start Q4 2021
- ✓ SORENTO fully enrolled Q4 2023
- **Target number of events for primary endpoint est. early 2026**

positano™

Polycystic liver Safety and efficacy Trial with subcutaneous Octreotide

- ✓ POSITANO fully enrolled Q1 2024
- ✓ Orphan drug designation in EU and US
- ✓ **Positive clinical study results in June 2025**
- **End-of-phase 2 meeting with FDA**

Commercial readiness for launch of CAM2029 in acromegaly

Pre-launch activities in US and EU

- In-depth market research
- Optimizing the distribution and supply chain model
- Payor interactions and advisory meetings
- Increasing awareness of Camurus among stakeholders

CAM2029 peak sales estimates >2 billion USD across indications¹⁻³


	TERRITORY	PATIENT POPULATION	EST. PEAK PATIENT SHARE	EST. PEAK SALES
ACRO ¹	EU/AUS	16,500 ⁴	20 – 35%	€30 – 65 million
	US	10,000	25 – 40%	\$150 – 280 million
NET ¹	EU/AUS	68,000 ⁴	30%	€300 – 400 million
	US	37,000	40%	\$1,200 – 1,500 million
PLD ¹	EU/AUS	15-18,000 ⁴	30 – 40%	€80 – 100 million
	US	12-13,000	30 – 40%	\$200 – 300 million

¹Globe Life Science 2020-22, data on file;

²Assuming €10-12.5ks (EU/AUS) and \$60-70K (US) per year net pricing in acromegaly, €15-20k (EU/AUS) and \$80-100K (US) per year net pricing in NET, and €17.5k (EU/AUS) and \$60K (US) per year net pricing in PLD

³Patient numbers extrapolated from EU4+UK estimates by assuming same prevalence across European countries and Australia





Early-stage programs


Several early-stage programs advancing

- ✓ Phase 1 study of CAM2056
- ✓ Positive data and assessments of multiple preclinical drug candidates, including long-acting incretins

Progress of clinical study of CAM2056

CAM2056 – once monthly FluidCrystal semaglutide

- ✓ Completed preclinical program met target profile
- ✓ All patients dosed in Phase 1 study evaluating pharmacokinetics, weight loss, tolerability and safety of CAM2056 in overweight or obese participants
- Top-line results expected Q4 2025



Potential indications

- Type 2 diabetes
- Weight management
- Inflammation
- Neuropsychiatric disorders
- Substance use disorders

License agreement with Lilly on long-acting incretins

Partnership focused on long-acting therapies based on FluidCrystal and Lilly's proprietary drug compounds

- Lilly obtained license to research, develop, manufacture and commercialize long-acting incretin products based on FluidCrystal
- Includes up to four Lilly proprietary drug compounds within the exclusivity scope:
 - Dual GIP and GLP-1 receptor agonists
 - Triple GIP, glucagon and GLP-1 receptor agonists
 - An option to include amylin receptor agonists

Camurus eligible to receive:

- Up to \$290 million in license fees, development and regulatory milestone payments
- Up to \$580 million in sales-based milestone payments
- Tiered mid-single digit royalties on global net product sales



Significant near-term opportunities

- Continued Buvidal growth in Europe and RoW
- Increasing Brixadi penetration in the US
- US market approval of CAM2029 in acromegaly
- Clinical results for CAM2029 and CAM2056
- Diversification through business development
- Positive financial outlook 2025 with expected high growth revenues (+45-61%) and profitability (+63-117%)



Camurus AB | Rydbergs torg 4, SE-224 84 Lund, Sweden
P +46 46 286 57 30 | info@camurus.com | camurus.com

Shareholders and analyst coverage

Shareholders as of 31 July 2025	Number of shares	% of capital	% of votes
Sandberg Development AB	18,280,692	30.6	30.6
Fourth Swedish National Pension Fund	2,808,776	4.7	4.7
Swedbank Robur Fonder	2,567,508	4.3	4.3
Fredrik Tiberg, CEO	1,500,000	2.5	2.5
Handelsbanken fonder	1,442,391	2.5	2.5
Vanguard	1,397,844	2.3	2.3
Avanza Pension	1,230,673	2.1	2.1
Capital Group	1,149,991	1.9	1.9
Afa Försäkring	1,008,883	1.7	1.7
SEB Funds	987,980	1.7	1.7
Carnegie Fonder	820,700	1.4	1.4
Norges bank	719,795	1.2	1.2
Länsförsäkringar Fonder	670,762	1.1	1.1
Baillie Gifford & Co	624,644	1.1	1.1
Jupiter Asset Management	620,160	1.1	1.1
Other shareholders	23,829,785	39.9	39.9
In total	59,660,584	100.0	100.0

Analysts

DNB Carnegie

Erik Hultgård

Handelsbanken

Suzanna Queckbörner

Jefferies

Shan Hama

Nordea

Viktor Sundberg

Pareto

Dan Akschuti

Stifel

Oscar Haffen Lamm

SEB

Christopher Uhde

ABG Sundal Collier

Georg Tigalov-Bjerke

Redeye*

Richard Ramanius

Experienced and committed management team



Fredrik Tiberg, PhD
President & CEO, CSO
In Company since 2002
Holdings: 1,500,000 shares, 42,000 employee options and 13,500 PSP units

Education: M.Sc. in Chem. Eng., Lund Institute of Technology, PhD and Assoc. Prof. Physical Chemistry, Lund University.
Previous experience: More than 20 years executive leadership experience from the pharmaceutical industry. Prof Physical Chemistry, Lund University; Visiting Prof at Oxford University; Section Head, Inst. for Surface Chemistry.



Anders Vadsholt
Chief Financial Officer
In Company since: 2025
Holdings: 2,300 PSP units

Education: M.Sc. In Corporate Law and Economics, Copenhagen Business School, and MBA, University of Melbourne
Previous experience: More than 25 years experience in corporate finance, venture capital, and the biotech industry, incl. Orphazyme A/S, MinervaX ApS, and Topotarget A/S.



Richard Jameson
Chief Commercial Officer
In Company since: 2016
Holdings: 29,193 shares and 6,082 PSP units

Education: B.Sc. in Applied Biological Sciences from University West of England
Previous experience: General Manager, UK & Nordics for Reckitt Benckiser (2010 – 2013) and Area Director Europe, Middle East and Africa for Indivior (2013 – 2016).



Fredrik Joabsson, PhD
Chief Business Dev. Officer
In Company since 2001
Holdings: 40,170 shares and 2,918 PSP units

Education: M.Sc. in Chemistry, PhD in Physical Chemistry, Lund University
Previous experience: More than 20 years of experience in pharmaceutical R&D, business development, alliance management and investor relations.



Markus Johnsson
Senior VP R&D
In Company since: 2003-2017, 2019-
Holdings: 16,000 shares, 9,500 employee options and 2,918 PSP units

Education: Ph.D. in physical chemistry and M.Sc. in chemistry from Uppsala University.
Previous experience: More than 20 years of experience from pharmaceutical development and project management



Maria Lundqvist
Head of Global HR
In Company since 2021
Holdings: 4,000 employee options and 2,918 PSP units

Education: B.Sc. in Business and Economics, Uppsala University.
Previous experience: More than 20 years of experience of leadership roles within Human Resources, including HR Director Nordics at Teva Pharmaceuticals and HR positions at Tetra Pak, Vestas and AstraZeneca.



Alberto M. Pedroncelli
Chief Medical Officer
In Company since 2023
Holdings: 1,000 shares, 20,000 employee options and 1,500 PSP units

Education: MD University of Milan. Ph. D. endocrinology post-graduate school University of London
Previous experience: Head of Clinical Development and Medical Affairs Recordati, Senior Leadership positions Novartis, clinician and research fellow Dept. Endocrinology, University Hospital Bergamo, Italy



Annette Mattsson
VP Regulatory Affairs
In Company since: 2017
Holdings: 2,004 shares and 2,918 PSP units

Education: Bachelor of Pharmacy, Uppsala University and Business Economics, Lund University
Previous experience: More than 25 years of experience within regulatory affairs, including European RA Director/Global RA Lead at AstraZeneca and Global RA Lead at LEO Pharma.



Agneta Svedberg
VP Clinical Dev.
In Company since: 2015
Holdings: 22,987 shares, 16,000 employee options and 2,918 PSP units

Education: M.Sc. In Radiophysics and B.Sc. In Medicine from Lund University, Executive MBA from Executive Foundation Lund
Previous experience: More than 25 years of experience in drug development, incl. as COO at Zealand Pharma, CEO of Cantargia, Senior VP Clinical Development at Genmab.



Behshad Sheldon
President Camurus Inc.
In Company since 2024
Holdings: 1,000 shares, 2,000 employee options and 2,918 PSP units

Education: B.Sc. in Neuroscience from University of Rochester
Previous experience: More than 25 years of experience from the international pharma industry, including President & CEO of Braeburn Pharmaceuticals and senior positions within Smithkline Beecham, Bristol-Myers Squibb and Otsuka Pharmaceuticals.



Susanne Lagerlund
VP, Technical Operations
In Company since 2023
Holdings: 250 shares, 9,500 employee options and 2,618 PSP units

Education: M. Sc. Chemical Engineering and studies Business Eonoics, Lund University
Previous experience: More than 30 years of experience from pharmaceutical industry, including Global Regulatory CMC Director at AstraZeneca, VP Regulatory Affairs at Cantargia, and Global Portfolio Lead at LEO Pharma.



Bo A. C. Tarras-Wahlberg
VP Legal & Group General Counsel
In Company since 2024
Holdings: 2,918 PSP units

Education: LLM from Lund University and studies at Queen Mary College
Previous experience: More than 20 years of experience as lawyer and from international senior legal positions, incl. as Assoc. General Counsel at Baxter, Gambro, legal private practice and as law clerk at District Court.